Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy

An unmet need remains for safe and effective treatments to induce and maintain remission in inflammatory bowel disease (IBD) patients. The Janus kinase (JAK) inhibitor, tofacitinib, has demonstrated robust eff...

Source: Journal of Inflammation - December 6, 2017 Category: Allergy & Immunology Authors: David T. Beattie, M. Teresa Pulido-Rios, Fei Shen, Melissa Ho, Eva Situ, Pam R. Tsuruda, Patrick Brassil, Melanie Kleinschek and Sharath Hegde Tags: Research Source Type: research